| Patient | Flannery O'Connor |
|---|---|
| Date of birth | 2001-03-25 |
| Identifiers | MRN HR-ML046-SYN; SSN (made up) 000-46-1853 |
| Document date | 2026-11-01 |
| Author | Augusta Pemberton-Diallo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for joint pain and swelling, fevers, fatigue, a facial rash, and protein in the urine in a writer of 25. Concerns: Painful, swollen hands and knees, fevers, tiredness, and a rash on her face, for three months; Wants a plain, complete answer about what is wrong, told to her directly, and asks that it not be shared with anyone she has not named; Afraid of losing her writing mornings to illness or treatment. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2026-04-13 | active | S |
| Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Methylprednisolone 500 mg intravenous infusion once daily for three days | One infusion daily for three days | Intravenous route | 2026-04-29 to 2026-05-01 | completed | S |
| Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months | Once daily, tapering | Oral route | 2026-04-29 | active | S |
| Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily | Two tablets twice daily | Oral route | 2026-04-29 | active | S |
| Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly | Once weekly by self-injection | Subcutaneous route | 2026-04-29 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-04-29 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven days | One capsule twice daily for seven days | Oral route | 2026-06-15 to 2026-06-21 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Ultrasound-guided percutaneous kidney biopsy: ISN/RPS class III (A) lupus nephritis, endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence, subendothelial deposits; no crescents, thrombotic microangiopathy, or interstitial fibrosis beyond 10 percent; no bleeding after the procedure | 2026-04-24 to 2026-04-24 | completed | S |
| Insertion of a levonorgestrel 52 mg intrauterine system, her choice for contraception before mycophenolate; pregnancy test negative | 2026-04-28 to 2026-04-28 | completed | S |
| Bone density scan (DXA) at the start of high-dose glucocorticoids: lumbar spine Z-score -0.4, femoral neck Z-score -0.2; normal for age | 2026-04-29 to 2026-04-29 | completed | S |
| Baseline eye examination for hydroxychloroquine with dilated fundus examination, spectral-domain optical coherence tomography, and automated 10-2 visual fields: normal; yearly screening from five years of use | 2026-06-29 to 2026-06-29 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-10 | Influenza vaccine, 2025-2026 season | completed | S |
| 2013-10-01 | HPV vaccine, 9-valent, series completed (dose 2 of 2) | completed | S |
| 2019-05-14 | Tdap vaccine | completed | S |
| 2026-04-22 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-04-22 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-07-27 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 2026-10-05 | Influenza vaccine, 2026-2027 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| December 1949 | Month-long hospital stay with an operation for a floating kidney | D (CLM-0004) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Systemic lupus erythematosus, first diagnosed as rheumatoid arthritis; he died of it in 1941 at 45 | 45 | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| Painful, swollen hands and knees, fevers, tiredness, and a rash on her face, for three months | active | S |
| Wants a plain, complete answer about what is wrong, told to her directly, and asks that it not be shared with anyone she has not named | active | S |
| Afraid of losing her writing mornings to illness or treatment | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 12.8 on 2026-10-26; Leukocytes [#/volume] in Blood by Automated count 7.9 on 2026-06-15; Lymphocytes [#/volume] in Blood by Automated count 1.2 on 2026-10-26; Platelets [#/volume] in Blood by Automated count 236 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-06-15; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 on 2026-10-26; Potassium [Moles/volume] in Serum or Plasma 4.6 on 2026-06-15; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 2026-10-26; Erythrocyte [Sedimentation Rate] in Blood by Westergren method 52 on 2026-04-13; C reactive protein [Mass/volume] in Serum or Plasma 0.6 on 2026-04-13; Protein/Creatinine [Mass Ratio] in Urine 0.35 on 2026-10-26; Erythrocytes [#/area] in Urine sediment by Microscopy high power field 2 on 2026-10-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-10-26; Pain severity - 0-10 verbal numeric rating [Score] - Reported 0 on 2026-10-26; Nuclear Ab [Titer] in Serum by Immunofluorescence 640 on 2026-04-22; DNA double strand Ab [Units/volume] in Serum 38 on 2026-10-26; Smith extractable nuclear Ab [Units/volume] in Serum 42 on 2026-04-22; Complement C3 [Mass/volume] in Serum or Plasma 96 on 2026-10-26; Complement C4 [Mass/volume] in Serum or Plasma 18 on 2026-10-26; Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay 6 on 2026-04-22; Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay 4 on 2026-04-22; Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum 3 on 2026-04-22; Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum 2 on 2026-04-22; dRVVT/dRVVT W excess phospholipid (screen to confirm ratio) 1.04 on 2026-04-22; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 on 2026-07-27; DXA Lumbar spine [Z-score] Bone density -0.4 on 2026-04-29; DXA Femur [Z-score] Bone density -0.2 on 2026-04-29; Cholesterol [Mass/volume] in Serum or Plasma 212 on 2026-07-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-07-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 2026-07-27; Triglyceride [Mass/volume] in Serum or Plasma 130 on 2026-07-27; Hemoglobin A1c/Hemoglobin.total in Blood 5.3 on 2026-07-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-05; Total score [AUDIT-C] 1 on 2026-10-05 [S]
Strengths and supports: Strengths: a sharp, ironic sense of humor and a steady religious faith; supports: friends and a writing community; she prefers to keep her health out of conversations about her work [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be established | resolved | confirmed | M25.50 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D). |
| Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be established | resolved | confirmed | R80.9 | S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit. |
| Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negative | active | confirmed | M32.19 | S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used. |
| Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney function | active | confirmed | M32.14 | S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used. |
| Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or less | active | confirmed | Z79.52 | S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low. |
| Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in place | active | confirmed | Z79.624 | S — Synthetic treatment status. |
| Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatment | active | confirmed | Z97.5 | S — Synthetic contraception, chosen by the patient. |
| Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoin | resolved | confirmed | N30.00 | S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 11 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-13 | Leukocytes [#/volume] in Blood by Automated count | 3.3 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-04-13 | Lymphocytes [#/volume] in Blood by Automated count | 0.8 | 10*3/uL | 1-4.8 10*3/uL | Low | S |
| 2026-04-13 | Platelets [#/volume] in Blood by Automated count | 138 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Albumin [Mass/volume] in Serum or Plasma | 3.3 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | <=33 U/L | Normal | S |
| 2026-04-13 | Erythrocyte [Sedimentation Rate] in Blood by Westergren method | 52 | mm/h | <=20 mm/h | High | S |
| 2026-04-13 | C reactive protein [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | <=0.5 mg/dL | High | S |
| 2026-04-13 | Protein/Creatinine [Mass Ratio] in Urine | 1.6 | g/g | <=0.2 g/g | High | S |
| 2026-04-13 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 18 | /[HPF] | <=2 /[HPF] | High | S |
| 2026-04-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-04-13 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S | ||
| 2026-04-22 | Nuclear Ab [Titer] in Serum by Immunofluorescence | 640 | {titer} | Negative at 1:40 or less; the EULAR/ACR entry criterion is 1:80 or higher | High | S |
| 2026-04-22 | DNA double strand Ab [Units/volume] in Serum | 186 | [IU]/mL | <=29 [IU]/mL | High | S |
| 2026-04-22 | Smith extractable nuclear Ab [Units/volume] in Serum | 42 | U/mL | <=19 U/mL | High | S |
| 2026-04-22 | Complement C3 [Mass/volume] in Serum or Plasma | 62 | mg/dL | 90-180 mg/dL | Low | S |
| 2026-04-22 | Complement C4 [Mass/volume] in Serum or Plasma | 8 | mg/dL | 10-40 mg/dL | Low | S |
| 2026-04-22 | Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay | 6 | U/mL | <=20 U/mL | Normal | S |
| 2026-04-22 | Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay | 4 | U/mL | <=20 U/mL | Normal | S |
| 2026-04-22 | Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum | 3 | U/mL | <=20 U/mL | Normal | S |
| 2026-04-22 | Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum | 2 | U/mL | <=20 U/mL | Normal | S |
| 2026-04-22 | dRVVT/dRVVT W excess phospholipid (screen to confirm ratio) | 1.04 | {ratio} | <=1.2 | Normal | S |
| 2026-04-22 | Protein/Creatinine [Mass Ratio] in Urine | 1.8 | g/g | <=0.2 g/g | High | S |
| 2026-04-22 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 22 | /[HPF] | <=2 /[HPF] | High | S |
| 2026-04-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-04-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-29 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-29 | Leukocytes [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-04-29 | Lymphocytes [#/volume] in Blood by Automated count | 0.9 | 10*3/uL | 1-4.8 10*3/uL | Low | S |
| 2026-04-29 | Platelets [#/volume] in Blood by Automated count | 151 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | <=33 U/L | Normal | S |
| 2026-04-29 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 26 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-04-29 | DXA Lumbar spine [Z-score] Bone density | -0.4 | {Z-score} | Z-score above -2.0 is within the expected range for age | Normal | S |
| 2026-04-29 | DXA Femur [Z-score] Bone density | -0.2 | {Z-score} | Z-score above -2.0 is within the expected range for age | Normal | S |
| 2026-07-27 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-07-27 | Leukocytes [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-27 | Lymphocytes [#/volume] in Blood by Automated count | 1 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 2026-07-27 | Platelets [#/volume] in Blood by Automated count | 212 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-27 | Albumin [Mass/volume] in Serum or Plasma | 3.8 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-07-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | <=33 U/L | Normal | S |
| 2026-07-27 | Protein/Creatinine [Mass Ratio] in Urine | 0.9 | g/g | <=0.2 g/g | High | S |
| 2026-07-27 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 6 | /[HPF] | <=2 /[HPF] | High | S |
| 2026-07-27 | DNA double strand Ab [Units/volume] in Serum | 72 | [IU]/mL | <=29 [IU]/mL | High | S |
| 2026-07-27 | Complement C3 [Mass/volume] in Serum or Plasma | 84 | mg/dL | 90-180 mg/dL | Low | S |
| 2026-07-27 | Complement C4 [Mass/volume] in Serum or Plasma | 13 | mg/dL | 10-40 mg/dL | Normal | S |
| 2026-07-27 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-07-27 | Cholesterol [Mass/volume] in Serum or Plasma | 212 | mg/dL | <=199 mg/dL | High | S |
| 2026-07-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-07-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=99 mg/dL | High | S |
| 2026-07-27 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-07-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3 | % | <=5.6% | Normal | S |
| 2026-07-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-07-27 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S | ||
| 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-10-26 | Leukocytes [#/volume] in Blood by Automated count | 5.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-26 | Lymphocytes [#/volume] in Blood by Automated count | 1.2 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 2026-10-26 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | <=33 U/L | Normal | S |
| 2026-10-26 | Protein/Creatinine [Mass Ratio] in Urine | 0.35 | g/g | <=0.2 g/g | High | S |
| 2026-10-26 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 2 | /[HPF] | <=2 /[HPF] | Normal | S |
| 2026-10-26 | DNA double strand Ab [Units/volume] in Serum | 38 | [IU]/mL | <=29 [IU]/mL | High | S |
| 2026-10-26 | Complement C3 [Mass/volume] in Serum or Plasma | 96 | mg/dL | 90-180 mg/dL | Normal | S |
| 2026-10-26 | Complement C4 [Mass/volume] in Serum or Plasma | 18 | mg/dL | 10-40 mg/dL | Normal | S |
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-10-26 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 0 | {score} | S | ||
| 2026-06-15 | Leukocytes [#/volume] in Blood by Automated count | 7.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-15 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-06-15 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-05 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 168 | cm | S |
| 2026-04-13 | Body weight | 60 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 96 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 37.9 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-22 | Body height | 168 | cm | S |
| 2026-04-22 | Body weight | 59.6 | kg | S |
| 2026-04-22 | Body mass index (BMI) [Ratio] | 21.1 | kg/m2 | S |
| 2026-04-22 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-04-22 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-04-22 | Heart rate | 92 | /min | S |
| 2026-04-22 | Respiratory rate | 16 | /min | S |
| 2026-04-22 | Body temperature | 37.6 | Cel | S |
| 2026-04-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-29 | Body height | 168 | cm | S |
| 2026-04-29 | Body weight | 59.8 | kg | S |
| 2026-04-29 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-04-29 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-04-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-04-29 | Heart rate | 84 | /min | S |
| 2026-04-29 | Respiratory rate | 14 | /min | S |
| 2026-04-29 | Body temperature | 37 | Cel | S |
| 2026-04-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-27 | Body height | 168 | cm | S |
| 2026-07-27 | Body weight | 63.4 | kg | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-07-27 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-07-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-07-27 | Heart rate | 76 | /min | S |
| 2026-07-27 | Respiratory rate | 14 | /min | S |
| 2026-07-27 | Body temperature | 36.7 | Cel | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-26 | Body height | 168 | cm | S |
| 2026-10-26 | Body weight | 62 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 72 | /min | S |
| 2026-10-26 | Respiratory rate | 14 | /min | S |
| 2026-10-26 | Body temperature | 36.6 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-06-15 | Body height | 168 | cm | S |
| 2026-06-15 | Body weight | 62.4 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 84 | /min | S |
| 2026-06-15 | Respiratory rate | 14 | /min | S |
| 2026-06-15 | Body temperature | 37.3 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-05 | Body height | 168 | cm | S |
| 2026-10-05 | Body weight | 62.2 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 70 | /min | S |
| 2026-10-05 | Respiratory rate | 14 | /min | S |
| 2026-10-05 | Body temperature | 36.6 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-04-13 | Primary care visit for joint pain and swelling, fevers, fatigue, a facial rash, and protein in the urine in a writer of 25 | finished | S |
| 2026-04-22 | Diagnosis of systemic lupus erythematosus with the rheumatology consultation the same day; vaccinations before immunosuppression | finished | S |
| 2026-04-29 | Kidney biopsy result: class III lupus nephritis; start of pulse methylprednisolone, prednisone, mycophenolate, and belimumab | finished | S |
| 2026-07-27 | Three-month response assessment for lupus nephritis and glucocorticoid taper | finished | S |
| 2026-10-26 | Six-month response assessment: complete renal response; prednisone 5 mg; pregnancy planning | finished | S |
| 2026-06-15 | Same-day sick visit for bladder symptoms on immunosuppression | finished | S |
| 2026-10-05 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Inflammatory arthritis with fever, rash, cytopenias, and an abnormal urine: blood count, chemistry, ESR and CRP, urine microscopy and protein-to-creatinine ratio today; ANA, anti-dsDNA, anti-Sm, complements, and antiphospholipid antibodies; no NSAIDs with protein in the urine | completed | GL-EULAR-ACR-CRIT-2019, GL-ACR-LN-2024 | S |
| Rheumatology consultation within ten days, to confirm the diagnosis, stage organ involvement, and plan treatment with her | completed | GL-EULAR-SLE-2023 | S |
| Disclosure: every result explained to her directly and in plain words, with a written copy; her health shared only with the people she names | completed | GL-EULAR-SLE-2023 | S |
| Sun protection: broad-spectrum sunscreen SPF 50 or higher, a wide-brimmed hat, and shade in the middle of the day | completed | GL-EULAR-SLE-2023 | S |
| Hydroxychloroquine 300 mg daily (5 mg/kg) for every patient with lupus, long term, with a baseline eye examination within the first year and yearly screening after five years | completed | GL-EULAR-SLE-2023, GL-AAO-HCQ-2016 | S |
| Kidney biopsy for proteinuria above 0.5 g/g with an active sediment, to class the nephritis before treatment | completed | GL-ACR-LN-2024 | S |
| Vaccinations before immunosuppression: PCV20 and recombinant zoster dose 1 now, zoster dose 2 after one to two months, seasonal influenza and COVID-19; no live vaccines on immunosuppression; hepatitis B, hepatitis C, and HIV screening | completed | GL-ACR-VAX-2022, GL-CDC-IMZ-MC-2026 | S |
| Angiotensin receptor blocker (losartan) for proteinuria and blood pressure, target below 130/80 mmHg, with potassium and creatinine two to four weeks after starting | completed | GL-ACR-LN-2024, GL-CMID-2026 | S |
| Contraception before mycophenolate: highly effective method of her choice (levonorgestrel intrauterine system); pregnancy test before starting; pregnancy planning later for at least six months of quiet disease on pregnancy-compatible medicines | completed | GL-ACR-REPRO-2020, GL-FDA-MMF-2026 | S |
| Class III lupus nephritis: methylprednisolone 500 mg daily for three days, then prednisone 30 mg tapered to 5 mg a day or less by six months; mycophenolate mofetil 2 g a day with belimumab, continued for three to five years after a complete response; blood counts weekly for the first month, twice monthly for the next two, then monthly; urine protein-to-creatinine ratio, urine sediment, creatinine, anti-dsDNA, and complements every three months | completed | GL-ACR-LN-2024, GL-EULAR-SLE-2023, GL-FDA-MMF-2026, GL-FDA-BELIMUMAB-2026 | S |
| Bone protection on glucocorticoids: baseline DXA, vitamin D3 and calcium from food, weight-bearing exercise; report new hip, groin, or knee pain at once so avascular necrosis can be looked for with MRI | completed | GL-ACR-GIOP-2022, GL-EULAR-SLE-2023 | S |
| Cardiovascular risk: blood pressure at every visit, lipids and HbA1c at three months on glucocorticoids, no smoking, activity, and a lower glucocorticoid dose | completed | GL-EULAR-SLE-2023 | S |
| Writing life: treatment visits and infusions booked in the afternoons, belimumab self-injected at home, fatigue managed with graded activity and sleep; her illness kept out of conversations about her work unless she chooses otherwise | completed | GL-EULAR-SLE-2023 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Establish the diagnosis within two weeks and hear it directly, in plain words | 2026-04-22 | completed | Told directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summary | S |
| Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months | 2026-10-26 | completed | Ratio 1.8 at diagnosis, 0.9 at three months, 0.35 at six months, a complete response; creatinine 0.8 throughout | S |
| Prednisone 5 mg a day or less by six months, with withdrawal considered later | 2026-10-26 | completed | 5 mg a day at six months | S |
| Write at least four mornings a week through treatment | 2026-12-31 | active | Writing five mornings a week by three months | S |
| No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines | 2026-12-31 | active | Intrauterine system in place; pregnancy planning discussed | S |